Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: As hydrochloride: Initially, 50-75 mg daily in 3-4 divided doses; may be increased to 100 mg daily after 3 or 4 days. Maintenance: Mild symptoms: 5-15 mg 3-4 times daily. Moderately severe symptoms: 10-25 mg 3-4 times daily. Severe symptoms: Up to 225 mg daily. A single daily dose is often adequate for maintenance therapy. Patients with resistant mental and emotional disturbances may require wk or mth of treatment.
Elderly: and debilitated: Reduce dose.
Chống chỉ định
Coma, severe CNS depression.
Thận trọng
CNS depression. Parkinson's disease. Patients with haemodynamic instability; bone marrow suppression; predisposition to seizures; subcortical brain damage; severe cardiac, hepatic, renal, respiratory disease. Patients at risk of pneumonia. Breast cancer or other prolactin-dependent tumours. May alter temperature regulation or mask toxicity of other drugs. Patients at risk of orthostatic hypotension. Decreased GI motility, urinary retention, benign prostatic hyperplasia, xerostomia or visual problems. May impair ability to drive or operate machinery. Pregnancy and lactation.
Tác dụng không mong muốn
Orthostatic hypotension, tachycardia, arrhythmia; extrapyramidal reactions, mental depression, altered central temperature regulation, sedation, drowsiness, restlessness, anxiety, hyperactivity, euphoria, seizure; pruritus, rash, photosensitivity; menstrual irregularities, oedema of breasts, galactorrhoea, gynaecomastia; constipation, xerostomia, nausea, salivation, wt gain/loss; urinary retention, priapism; leukopenia, leukocytosis; blurred vision, retinal pigmentation; decreased diaphoresis.
Potentially Fatal: Neuroleptic malignant syndrome (NMS).
Quá liều
Symptoms: Deep sleep, extrapyramidal symptoms, cardiac arrhythmias, seizures, hypotension. Management: Symptom-directed and supportive.
Tương tác
Increased risk of antipsychotic-related extrapyramidal symptoms with central acetylcholinesterase inhibitors, metoclopramide. Therapeutic response may be inhibited by anticholinergics (e.g. benztropine, trihexyphenidyl, biperiden, TCAs, antihistamines, disopyramide) and anticholinergic crisis may occur. May have additive hypotensive effects with antihypertensive agents, trazodone. May inhibit the effect of bromocriptine on prolactin levels. May cause additive sedation with barbiturates, benzodiazepines, opioid analgesics, ethanol. May produce neurotoxicity with lithium. Serum concentration may be increased with propranolol, sulfadoxine-pyrimethamine.
Potentially Fatal: Amphetamines may increase psychotic symptoms; may reduce efficacy of amphetamines. May inhibit antiparkinsonian effect of levodopa.
Tương tác với thức ăn
Additive CNS depression may occur with kava kava, gotu kola, valerian, St John's wort.
Tác dụng
Description: Molindone is a dihydroindoline antipsychotic with general properties similar to those of chlorpromazine.
Duration: 24-36 hr.
Absorption: Readily absorbed after oral doses; peak concentrations of unchanged drug within about 1.5 hr.
Metabolism: Hepatic; rapidly and extensively metabolised.
Excretion: Via urine and faeces (mainly as metabolites and <2-3% as unchanged drug). Elimination half-life: 1.5 hr.
Bảo quản
Store at 25°C (77°F). Protect from light.
Phân loại MIMS
Thuốc chống loạn thần
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Molindone từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in